Coeptis Therapeutics to merge with Dogecoin miner Z Squared; biopharma spun out

Z Squared Inc.

Coeptis to spin out biopharma; Z Squared becomes wholly-owned subsidiary focused on Dogecoin mining.
Z Squared shareholders receive Coeptis equity for 9,000 DOGE mining machines; minimum asset value of $660.3M required.
Post-close leadership: Z Squared CEO David Halabu becomes CEO; Michelle Burke COO; Dave Mehalick exits board.
Closing expected Q3 2025; conditions include shareholder and regulatory approvals and Nasdaq listing.
Combined company to rebrand as Z Squared, aiming to be largest U.S. publicly-traded Dogecoin miner.

item 1.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001683168-25-002856
form_type: 8-K
ticker: ZSQR
cik: 0001759186
company_name: Z Squared Inc.
filed_at: 2025-04-28T23:59:59+00:00
discovered_at: 2026-05-14T18:02:49.612810+00:00
generated_at: 2026-05-23T05:07:42.406941+00:00
sec_items: ["1.01", "7.01", "9.01"]
event_type: m_and_a
sentiment: neutral
materiality_score: 0.9
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001683168-25-002856
json_url: https://secwatch.observer/filing/0001683168-25-002856.json
markdown_url: https://secwatch.observer/filing/0001683168-25-002856.md
text_url: https://secwatch.observer/filing/0001683168-25-002856.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316825002856/0001683168-25-002856-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316825002856/coeptis_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001683168-25-002856

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.